Med·Invest | Medical Device Investment Highlights (Dec 14–28, 2024)

1. TrendTec Completes Over 100 Million Yuan Financing to Achieve Domestic Substitution of Joint Materials

Medpark, the Jiangsu Medical Device Technology Industrial Park, announced that its invested and incubated company, TrendTec (Suzhou Chengtai New Material Technology Co., Ltd.), has completed an equity financing round exceeding 100 million yuan. This round was led by Vivo Capital with participation from a fund under CICC Capital. The funds will be used for production line construction and subsequent product iteration and R&D.

TrendTec, formerly known as Suzhou TrendTec Medical Device Co., Ltd., was established in 2020 and is primarily dedicated to the research, development, production, and sales of ceramic materials for hip joints. Relying on the technical expertise of two Tsinghua University Ph.D.s in Materials Science with over 30 years of accumulated experience, TrendTec has successfully completed the R&D and production of ceramic femoral heads and liners (the core components of hip joints), with product performance now fully comparable to leading international companies. The company has been approved for the 2023 Ministry of Industry and Information Technology and National Medical Products Administration "Challenge Project," the 2023 Jiangsu Province Major Achievement Transformation Project, and has been honored with titles such as Jiangsu Province Double Innovation Talent, Double Innovation Doctor, Gusu Entrepreneurial Leading Talent, Suzhou New District Entrepreneurial Leading Talent, National Technology-Oriented SME, and Innovative SME.

2. Brain-computer interface (BCI) company Precision announces completion of $102 million Series C financing

Brain-computer interface (BCI) company Precision Neuroscience Corporation (Precision) announced the successful completion of a $102 million Series C financing round, led by General Equity Holdings, with participation from B Capital, Duquesne Family Office, the investment company of Stanley F. Druckenmiller, and Steadview Capital.

Precision has raised a total of $155 million in funding and is one of the best-funded companies in the brain-computer interface field.

 With new financing support, Precision will expand its team, advance its clinical research efforts, and refine future versions of its artificial intelligence brain implant. This implant is designed to enable severely paralyzed users to operate digital devices such as computers and smartphones using only their thoughts. In the coming years, this system has the potential to redefine the meaning of physical disability, breaking down barriers to communication, employment, and independence.

3. Eli Radiopharma Completes RMB 100 Million Angel Financing Round, Accelerating Innovation and Strategic Development in Radiopharmaceuticals

Eli Radiopharma was founded in 2024 as a radiopharmaceutical company dedicated to the innovation and development of radiopharmaceuticals and high-tech applications. Established by a team of experienced scientists and entrepreneurs, the company focuses on the fields of oncology and neuroscience. Adhering to the core concept of "innovation-driven, precision medicine," Eli Radiopharma is committed to providing more precise diagnostics and effective treatment solutions for patients worldwide by developing cutting-edge radiopharmaceuticals, creating a healthier and longer life journey for humanity.

This round of financing was jointly led by Tylon Investment and Origimed Capital, with participation from PineLight Capital, Taiyu Investment, Mint Venture Capital, and Lula Capital. The completion of this financing marks an important step for Eli Radiopharma in achieving its vision, reflecting its commitment to the strategic goal of integrating diagnosis and treatment with radiopharmaceuticals, and laying a solid foundation for the company's future sustainable growth and development.

The funds raised will be used to build Eli Radiopharma's leading radiopharmaceutical innovation platform, further enhancing the company's R&D capabilities. In addition, the funds will also help accelerate the progress of the company’s clinical projects and expand the team size, comprehensively advancing the overall strategic development process of Eli Radiopharma.

4. V-Med C Round Financing Successfully Concluded, Hundreds of Millions in Funds to Propel New Chapter in Healthcare

Since its establishment in July 2018, Weike Medical has consistently focused on addressing significant clinical needs in the cardiovascular field, particularly in the area of heart failure and minimally invasive interventions for structural heart disease. With core competencies in research and development, technical services, production, and sales, the company is committed to building an innovative medical device platform that provides full-cycle cardiovascular solutions, offering advanced products and treatment options to patients and doctors worldwide.

The company has successfully completed its C-round financing, raising several hundred million RMB, fully led by Bohua Capital, a well-known investment institution in Liangxi District, Wuxi City. This round of financing will provide strong financial support for Weike Medical in areas such as product development, market expansion, and international strategic layout.

Currently, the product line of Weike Medical covers multiple cardiovascular treatment fields, including atrial shunt devices and various active devices for heart failure prevention and treatment, patent foramen ovale occluders for cardioembolic stroke prevention, transcatheter aortic valve replacement systems for treating valvular diseases, as well as related surgical accessory consumables.

It is worth mentioning that the patent foramen ovale closure device and multiple配套耗材have been successfully commercialized.

5. 3D Medicines' Pathology AI Platform "Shuda Technology" Completes Nearly RMB10 Million Angel Round Financing

3D Medicines Diagnostics is one of the early companies in China engaged in precision medicine, having built a multi-technology cross-disciplinary R&D platform that includes NGS sequencing and genomic data processing technologies, exosome technology, rapid qPCR technology, and AI-based digital image processing technology. Digitization and datafication are among the foundational elements of precision medicine. Shuda Technology, established in 2023, is an innovative pathology AI platform incubated by 3D Medicines Diagnostics and represents a natural extension of capability and data accumulation in the clinical practice of precision medicine. The funds from this financing round will be invested into the research, development, and commercial operation of Shuda Technology’s related products, injecting robust momentum for the continuous transformation of innovative achievements.

Combining digital image processing technology with years of pathology testing experience, Shuda Technology is dedicated to providing intelligent, full-process pathology image analysis solutions for medical and scientific researchers. Its flagship product, APTime, is a cost-effective AI-based pathology image analysis system widely used in medical fields such as oncology, immune diseases, cardiovascular, neurology, endocrinology, and more. Shuda Technology also provides clinical institutions with AI-powered medical image diagnostic products and comprehensive solutions, meeting unfulfilled clinical needs with high efficiency and accuracy, while promoting hierarchical diagnosis and treatment as well as the broader availability of quality medical resources.